COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
Julián Esteban Barahona-CorreaCamilo Rueda-OrtizMaría-José LópezSandra GualteroMónica Arevalo-ZambranoPublished in: SAGE open medical case reports (2023)
Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.
Keyphrases
- acute lymphoblastic leukemia
- sars cov
- allogeneic hematopoietic stem cell transplantation
- respiratory syndrome coronavirus
- ejection fraction
- end stage renal disease
- newly diagnosed
- stem cells
- patient reported outcomes
- clinical practice
- acute myeloid leukemia
- decision making
- hodgkin lymphoma
- diffuse large b cell lymphoma
- smoking cessation